Elmet Group Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Increased 35.2% year-over-year to $66.4 million, up from $49.1 million in Q2 2025.

Gross Profit: Rose 63.7% to $16.6 million, resulting in a gross margin of 25% compared to 20.7% in the prior year.

Adjusted EBITDA: Increased 57.2% to $8.9 million, up from $5.6 million in Q2 2025.

Net Loss: Reported at $4.5 million or $0.16 per share, compared to net income of $1.2 million or $0.06 per share in Q2 2025.

Adjusted Net Income: Increased to $5.2 million or $0.18 per share, up from $2.8 million or $0.14 per share in Q2 2025.

Backlog: Reached $131.5 million, a 55% increase from the previous year.

2Strategic Updates and Business Highlights

Elmet Group focuses on securing the U.S. critical materials supply chain, serving sectors including aerospace, defense, industrial, and medical.

Significant operational improvements and strategic sourcing agreements have allowed the company to navigate rising tungsten and molybdenum prices effectively.

Announced increased ownership stake in EQ Resources to enhance supply chain resilience.

Secured $4.3 million in funding to advance domestic manufacturing capabilities for molybdenum-based products.

Increased staffing and operational support in CMC factories have positively impacted productivity.

3Forward Guidance and Outlook

Management remains optimistic about the long-term demand driven by defense spending and reshoring initiatives.

Anticipates continued growth in backlog and revenue, particularly in the aerospace and defense sectors.

Plans to leverage strategic collaborations and investments to enhance competitive positioning and operational capacity.

4Bad News, Challenges, or Points of Concern

Operating expenses surged 251.2% to $24.2 million, largely due to equity-based compensation related to the IPO and compliance costs.

The company reported a significant net loss, influenced by IPO-related expenses and fluctuating order patterns from key customers, particularly in the medical sector.

There is uncertainty regarding the timing and magnitude of larger multiyear orders from defense primes, which have not yet reflected in the backlog.

Challenges in the EMP division's margins due to operational issues and rising material costs.

5Notable Q&A Insights

Munitions Orders: Management noted that significant missile defense orders have not yet flowed into their backlog, with only modest orders received.

Medical Customer Volatility: A major medical customer has caused fluctuations in backlog, with a notable drop from $12 million to $5.5 million year-over-year.

Margin Improvement: While CMC margins improved, EMP margins faced challenges due to rising material costs and operational difficulties.

Future Opportunities: Management is optimistic about capturing higher-margin business in the ADG space and expects to maintain a target EBITDA margin of 30% in the next 4-5 years. Overall, while Elmet Group demonstrated strong revenue growth and backlog expansion, it faces challenges related to operational costs and customer order volatility, particularly in the medical sector. The company remains well-positioned to capitalize on favorable market trends in defense and critical materials.